Become a Member

“One Device to End All Disease … And It Costs Less Than $50”

What's the MEMS stock being teased by Michael Robinson's Radical Technology Profits?

By Travis Johnson, Stock Gumshoe, April 28, 2015

This article was originally published on August 13, 2013, around the time this teaser ad pitch was first circulated. The ad is still largely the same today and is circulating heavily again, and it is clearly still teasing the same company, so we’re just re-posting this article for all our newer readers who have questions… without any updates or edits. The spiel about this “one device to end all disease” is now apparently being used to pitch both the $2,000 Radical Technology Profits newsletter and the $99 Nova-X Report, both helmed by Michael Robinson at Money Map Press, so you might have seen similar spiels come from either of those publications.

The stock teased is at very nearly the same price as it was two ago when we originally covered it (it was around $8.50 then, just over $9 now), and the story is more or less the same (though I haven’t checked the detailed progress of any of their operations) — revenue has fallen for five years in a row, but estimates have started to rise again for 2015 and 2016 so analysts think they will start to grow again. It now trades at a forward PE of 14 on 2016 earnings, and at about 22X expected 2015 earnings (though long term growth expectations among analysts remain very low, about 5%). The dividend amount remains unchanged at 10 cents/quarter, so they still carry an anticipated yield in the neighborhood of 4.3%, close to what it was a couple years ago.

—–from 8/15/13——-

Radical Technology Profits, edited by Michael Robinson over at Money Map Press, is one of the newsletters that, like Breakthrough Technology Alert or the many other competitors, aims to get in early on technology and biotech stories — and also like most of these letters, they pitch their ideas by selling a big picture story that weaves some little company’s product into a larger and more easily identified trend that sounds entirely plausible.

Which isn’t to say that they’re all bad ideas — far from it, I’m sure these kinds of “breakout technology” newsletters all have some dramatic winning picks in their portfolio. The problem is that they all sound like great ideas, and given the bleeding edge nature of most of the technologies they pitch, and the small nature of many of the stocks, the assumption has to be that the major winners will make up for the large number of failures.

The smaller the stocks are that you count on for world-changing returns, the more diversified you need to be — or, I suppose, the more expert and prescient you have to be, though it’s dangerous to start thinking that you can predict things well enough to have a concentrated portfolio of small cap technology names.

But I’m not here to lecture you on how to think about investing in breakthrough technologies — I’m here to try to figure out who Michael Robinson is teasing in his latest ad as the beneficiary of this latest breakout trend. Here’s how he puts it in the email I received today:

“I’m going on record to say that this technology is so overwhelmingly transformative, that I’m comparing it to the internal combustion engine. It will change the way you do everything now and in the future. It’s now creating the Fourth Revolution in the industry. I kid you not, it’s that big.”

So, no shyness there. What is the technology? Here’s more from the ad:

“The End of Disease May Soon Become a Reality Thanks to MEMS

“Micro-Electro-Mechanical Systems

“If that name sounds high tech that’s because it is.

“And if you want to live a long and healthy life, without the fear of disease…

“You’ll want to watch this short presentation to the end because…

“MEMS are the Only Existing Technology That Could Eradicate the Dangers of Disease, Add 30 Healthy Years to Your Life…

“And Cost Less Than $50

“And here’s where it gets really exciting for someone in my line of work.

“Today, the patents for the MEMS set to end disease….

“They’re controlled by one tiny, unknown company.

“They Have Been Cleared By the FDA

You can see the whole presentation if you like here (or read the transcript), it’s a very long one and Robinson talks about how MEMS technology can allow for tiny sensors, powered by body heat, that are implanted under your skin and can alert your smartphone (which will then call your doctor) about changes in your body chemistry that indicate the pending risk of a heart attack. Among many other things, like smart cities with pollution and light sensors all around, and smart arrays of MEMS chips underground to track seismic activity and help to find oil and gas reserves..

So which company is it that he says controls the patents to all this MEMS stuff? After giving examples of a few pharma companies whose stocks skyrocketed on the back of multibillion dollar drugs to address some of the same diseases that can be helped by MEMS technology, he starts to throw in a few clues:

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


“A Tech Company 1/30th the Size of These ‘Big Pharma’ Titans, Developed a MEMS Technology That Could End All Heart Disease.

“And it Controls the Patents.

“There is a very simple way for you to get a slice of this company’s patent profits for less than $9. So you’ll be able to cheaply get in, on the ground floor…”

Now, the examples he gave right before that were Pfizer and Bristol-Myers Squibb — so keep that in mind, the stock might not be that tiny. To be 1/30 the size of those titans you’d be talking about a stock with a market cap between $2 billion and $7 billion. Roughly speaking.

Some more clues:

“First Off, They Produce the Lion’s Share of All MEMS Devices.

“Currently, they can produce 4 million devices a day. That’s more than anyone else in the world. And their production capabilities are growing exponentially each year.

“Which is why the companies that turn to them for MEMS technology are a who’s who of Silicon Valley and the Fortune 500 companies.

“Apple, Blackberry, Dell, Bosch, Continental, Delphi, Delta, Denso, Ericsson, Hewlett-Packard, Hitachi, HTC, Magnetti Marelli, Motorola, Nokia, Philips, Samsung, Seagate, Sony, Western Digital, and Cisco…”

And …

“They Have Also Captured and Secured Total Market Share Domination For All Major Operating Systems.

  • They have an astounding 75% of the Apple/iOS market.
  • 31.4% of the Android market.
  • And 54.4% of the Windows Operating Systems market.

“That’s over 4 times greater than the next closest competitor.

“So when a company is developing a MEMS health technology, and they want to ensure it is scalable across all operating systems both mobile and computer…

“They only have one clear choice.”

And they have a strong patent pipeline, we’re told:

“While this one company controls the Patent Pipeline for the most important MEMS breakthroughs for ending disease…

“Medical MEMS form just one block of their entire 800-patent portfolio.”

So … dominant position in MEMS chips for current mobile phones and tablets, strong patent portfolio with 800+ patents, largest producer of MEMS chips with capacity for four million chips a day, and a stock price under $9. This can only be …

ST Microelectronics (STM)

I know, sorry — this is a big one that you’ve probably already heard of. And it’s been quite weak over the past decade, thanks in part to Asian and US competition (Texas Instruments, all the analog chip makers, etc.) and in part to the weak European economy and currency issues. But it’s probably still the largest European chipmaker, and it was one of the pioneers of MEMS technology and does indeed have the capability of producing four million chips a day, and they do claim 800 patents. There’s quite likely a STM chip in your phone or your car right now.

The MEMS chips, including their medical sensors and other cutting edge products, are a relatively small part of the business, but one that’s growing. That division was less than 20% of sales last year, but the resurgence in growth there is probably a significant reason why the shares have recovered a bit recently. This is a big semiconductor company that might arguably be reasonably priced if you believe the analyst estimates about next year, and if you’re comfortable with their solid dividend (almost 5%), but they also are coming out of a really rough patch — they lost $2 billion last year, tough for a company with a market cap of only $7 billion. There’s a pretty good FT article about them here if you’d like more perspective.

And that’s about all I know about STM — they get teased every now and then as a MEMS pioneer and major patent holder (they’re in a big patent fight with Invensense (INVN) right now, among others), and I agree that MEMS is a huge growth industry, but I don’t know how their patent portfolio will hold up or how long it will be before MEMS chips make a big impact on STM’s bottom line. Most of the companies that are using sensors enabled by STM’s chips are either small or don’t widely publicize the connection, from what I can tell, and most of the early stage research breakthroughs that get trumpeted in this area lately are from not-yet-public little biotech companies.

STM is certainly an industry leader, with a big business in chips for smart phones and tablets and lots of other products, but my impression is that they’re not terribly nimble and they haven’t been very profitable in recent years. If you’ve an opinion to share on this one, feel free to spit it out with a comment below.

Irregulars Quick Take

Paid members get a quick summary of the stocks teased and our thoughts here. Join as a Stock Gumshoe Irregular today (already a member? Log in)
guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

136 Comments
Inline Feedbacks
View all comments
Bill Phillips
Guest
Bill Phillips
February 28, 2015 6:28 pm

Right now – Feb 27, 2015 – STM is setting up for a sell, not a buy on the daily chart. Ordinary garden variety ANOVA – Analysis of Variance, an implementation of quants’ statistical juju, shows the stock backing away from its upper 2-sigma boundary at 9.12 and heading back toward its mean at or near 8.75.
On the weekly chart a pullback also looks likelier than a further advance. After all, stocks are fractal. Reversion to the mean would take STM to 8.20 longer term. Sounds like a better level to buy.

Add a Topic
5971
Bill Phillips
Guest
Bill Phillips
February 28, 2015 6:42 pm

To clarify, I’m not looking at STM as a sell. Risk-reward is n.g. Possible option play though, if you have expertise in credit spreads.

wildesign
wildesign
February 28, 2015 7:28 pm

They are still recycling this same pitch? For what some of these newsletters charge at least they could offer something new. About a year ago a friend of mine joined one of these for about $2500 and recommended I join some other one. After some research I joined Stock Gumshoe. Best 49 bucks I ever spent. The other newsletters big sales pitch…was this same exact spiel. Thanks Travis. Since joining Gumshoe investing has gotten a whole lot more fun especially considering ideas are shared with a great group of pretty bright and savvy members.

Add a Topic
5971
👍 63
arch1
March 1, 2015 2:26 am
Reply to  wildesign

I agree I would have done better by investing in Solyndra than in news letters that cost $$$ thousands. GumShoe is a Best Buy.

👍 7797
Patricia
March 1, 2015 3:21 am
Reply to  arch1

Best Buy ever: $49.00 divided by 365 days = $0.1342 cents per day.

👍 689
Myron Martin
Irregular
February 28, 2015 11:51 pm

Refunds if not satisfied in 30 days is a “gimmick” even 90 days is questionable. As any truly experienced investor knows it may take anywhere from 6 months ora year or more for stocks to show their true colours. People who offer these short term refunds are counting on subscribers forgetting about asking for a refund before the deadline has passed.

Add a Topic
899
David Tillery
Guest
David Tillery
January 8, 2016 9:31 pm
Reply to  Myron Martin

U r correct, I think everything with Money Map Report is a ripoff. I signed up for several reports & I don’t get them.

Add a Topic
605
vivianlewis
vivianlewis
March 1, 2015 4:55 pm

I got a reader inquiry about STM so the promo is still going on. He is a techie and thinks the MEMC side may really be into something. I am still looking into that but in the meantime here is something for all of you. ST Microelectronics is a dual-national Franco-Italian company which is HQ’d in Switzerland to keep them from fighting each other along the Riviera. It has an American Depositary Receipt so it can trade on the NYSE. It is messily run because of its dual nationality.
As for whether it can apply for its MEMC health dingbats to the US Food & Drug Administration, you should know that foreign companies are allowed to apply for access to the US market all the time. As long as we are from the same human race as foreigners we can take the same medicines and use the same medical devices. Applying here gives foreign generic drugs a Good Housekeeping Seal of Approval. It makes it easier to get the EU CHMP and British and Japanese to allow the drug or procedure in to their countries. And because (alas) this is the country with the least effective control on pricing of drugs (despite Obamacare) you can make more moolah in the US than in France or Italy, where ST Microelectronics has its home and dual government controlling shareholders (who would not allow it to overchange the French or Italian healthcare systems but welcome grabbing bucks from our insurance companies and Uncle Sam.)

Add a Topic
229
Add a Topic
882
👍 166
Chuck Schwartz
Guest
April 17, 2016 1:29 am
Reply to  vivianlewis

The one thing Obamacare (actually an idea that came out of some Republicans in Massachusetts) did NOT do was negotiate any kind of price negotiation for prescriptions. Given the size of the Medicare wielding retired citizen community that ability would be a major one. Pharmaceutical manufacturer lobbyists blocked that part of the “deal” — my monthly Rx costs have increased nearly 600%

Billy
Guest
Billy
August 25, 2016 3:14 am
Reply to  Chuck Schwartz

Look into Blink health for your meds

ben4cleveland
Member
ben4cleveland
April 27, 2015 5:23 am

http://www.answers.com/Q/Which_company_holds_the_primary_MEMS_patents

I bought Tessera (TSRA) on this tip, if my research was mistaken then I have made around 50% on dumb luck.

👍 1
Suzanne
Member
April 30, 2015 10:32 am
Reply to  ben4cleveland

I have a wonderful coffee mug inscribed, ” No amount of planning will ever replace dumb luck.” It is not a market oriented cup but a life comment ala Forrest Gump.

Add a Topic
3838
Bharat
Guest
Bharat
June 21, 2015 1:24 pm
Reply to  Suzanne

Helo, Suzanne!
Long back, a famous man on one of his immumerable campaign trails said, ‘I don’t need good Generals to win, I need lucky ones’. Even in the market Lady Luck is irreplaceable…
That was Napoleon, just as relevant today.
The best!
Bharat

votedemout
votedemout
June 8, 2015 1:57 pm

Fidelity Equity Summary scores STM Bearish at 1.5 out of 10 and INVN Very Bearish at .6. Both are followed by 8 analysts, so none of them think these companies are ripe for acquisition at this point.

Add a Topic
3600
👍 2
votedemout
votedemout
June 8, 2015 1:59 pm

I should have said most of them, as there is an analyst who thinks they are buys.

👍 2
Lucid
Member
Lucid
June 20, 2015 11:15 am

Just received an email 2 days ago with this long, annoying advertisement video in it. No way in hell I watch that whole thing, thanks Travis, good man!

thebearsmith
June 21, 2015 11:21 am

Travis’ Irregulars is the best $49 I’ve ever spent! Thank you, Travis!

👍 7
Cheryl Pimental
Guest
Cheryl Pimental
September 9, 2015 4:08 pm

I am just wondering what you think of FARE (World Moto). It’s a penny stock that seems to have some really interesting promise. They just started producing the world’s first motor cycle taxi meter ($1B market) and they have YES app and HAIL YES app. in Thailand (where the two US expats who started the company live) to hire motor cycle taxis who will complete a shopping mission for you or deliver a package…. They have patents pending for the meter in 50+ countries that all heavily use motor cycle taxis. Here they are on YouTube: https://www.youtube.com/user/WorldMoto

Add a Topic
5971
Add a Topic
2841
Glenn henderson
Member
Glenn henderson
March 6, 2016 10:41 am

Take a look at NEO it has been steady tracking up. Bought it at around 2$.

Jeanne
Guest
Jeanne
June 21, 2016 10:52 pm

Hi , I am only interested in the pain devise suffering from pain.
Is their a website were i can by that?
Jeanne

Jeanne
Guest
Jeanne
June 21, 2016 10:54 pm

sorry about the spelling mistakes,but I am after the pain device.

levell murphy jr.
Guest
levell murphy jr.
July 16, 2016 5:45 pm

I need a partner , To help me bring my new UNIVERSAL MEDICAL ORGANIZER , to the market , that could really help a wider variety of patients
take their med’s daily. please e-mail me for pictures.

Rich Herrmann
Guest
Rich Herrmann
August 29, 2017 11:40 pm

Thanks Travis… This is the second time in the last few months I have found your post to be a well thought out commentary/wet blanket on some overly hyped next super bagger. I’m retired and trying to stretch a small pension and SS to eek out my retirement years. You have saved me more with good advice (MHO) before I jumped in with both feet into old loosers. Too bad these news letters not required to report when their supposedly current big hype was first published and how well it has done since first promoted.

Add a Topic
1209
Phillystyle
Guest
Phillystyle
November 14, 2017 12:39 am

Thanks for filling me on this I got an email about this so I decided to read more about what kind of B.S. He was selling because who actually cares about helping anyone else to become rich or to help complete strangers make huge profits on buying stock in a rising company or whatever. So anyways I’m glad you posted this! So thank you!

Add a Topic
5971

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info  
32
0
Would love your thoughts, please comment.x
()
x